vimarsana.com

Latest Breaking News On - Vor biopharma - Page 1 : vimarsana.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04.06.2024 - CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) - Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock .

DelveInsight Business Research, LLP: CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies - AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES

Vor Biopharma s (VOR) Outperform Rating Reaffirmed at Oppenheimer

Vor Biopharma s (VOR) Outperform Rating Reaffirmed at Oppenheimer
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Here are five things to know about 2024 Commencement speaker Siddhartha Mukherjee

Here are five things to know about 2024 Commencement speaker Siddhartha Mukherjee
thedp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedp.com Daily Mail and Mail on Sunday newspapers.

VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024

VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.